Drugs.com - Monthly Update October 2025

Описание: This month’s update dives into significant FDA approvals affecting key therapeutic areas. Discover groundbreaking treatments like Novo Nordisk’s Rybelsus for cardiovascular risk reduction in diabetes, and innovative solutions like Gazyva for lupus nephritis. Tune in to learn how these advancements could impact patient management and outcomes.

Rybelsus (semaglutide): Exploring its new role in cardiovascular risk reduction for adults with type 2 diabetes. https://www.drugs.com/rybelsus.html

Zoryve (roflumilast): A breakthrough steroid-free topical treatment for eczema in young children. https://www.drugs.com/zoryve.html

Gazyva (obinutuzumab): Approved for lupus nephritis, offering new hope for managing this serious kidney ailment. https://www.drugs.com/gazyva.html

Lynkuet (elinzanetant): A hormone-free option for alleviating hot flashes due to menopause. https://www.drugs.com/lynkuet.html

Lasix ONYU (furosemide injection): Introducing an at-home infusion method for heart failure patients dealing with edema. https://www.drugs.com/pro/lasix-onyu....

Jascayd (nerandomilast): A new approval to combat the progression of idiopathic pulmonary fibrosis. https://www.drugs.com/pro/jascayd.html

Chapters:
00:00 - Intro
00:40 - Rybelsus
01:36 - Zoryve Cream
02:17 - Gazyva
02:51 - Lynkuet
03:01 - Lasix ONYU
03:44 - Jascayd
04:16 - Outro

Follow Drugs.com:
X   / drugscom  
Facebook   / drugscom  
Signup to our newsletters https://www.drugs.com/newsletters/
Download the app https://www.drugs.com/apps/